Trials / Unknown
UnknownNCT01659502
Investigator's Initiated Phase II Study for Pancreatic Cancer Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Tiltan Pharma Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of TL-118 alone or in combination with pancreatic cancer chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TL-118 | TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-10-01
- First posted
- 2012-08-07
- Last updated
- 2013-12-05
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01659502. Inclusion in this directory is not an endorsement.